JP7621728B2 - プロテアーゼ活性化受容体２のモジュレーター - Google Patents

プロテアーゼ活性化受容体２のモジュレーター Download PDF

Info

Publication number
JP7621728B2
JP7621728B2 JP2018544771A JP2018544771A JP7621728B2 JP 7621728 B2 JP7621728 B2 JP 7621728B2 JP 2018544771 A JP2018544771 A JP 2018544771A JP 2018544771 A JP2018544771 A JP 2018544771A JP 7621728 B2 JP7621728 B2 JP 7621728B2
Authority
JP
Japan
Prior art keywords
peptide
seq
amino acid
par2
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018544771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537529A (ja
JP2018537529A5 (enExample
Inventor
ルービー，リチャード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oasis Pharmaceuticals LLC
Original Assignee
Oasis Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oasis Pharmaceuticals LLC filed Critical Oasis Pharmaceuticals LLC
Publication of JP2018537529A publication Critical patent/JP2018537529A/ja
Publication of JP2018537529A5 publication Critical patent/JP2018537529A5/ja
Priority to JP2022145694A priority Critical patent/JP2022179508A/ja
Priority to JP2024207359A priority patent/JP2025036429A/ja
Application granted granted Critical
Publication of JP7621728B2 publication Critical patent/JP7621728B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2018544771A 2015-11-13 2016-11-11 プロテアーゼ活性化受容体２のモジュレーター Active JP7621728B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022145694A JP2022179508A (ja) 2015-11-13 2022-09-13 プロテアーゼ活性化受容体２のモジュレーター
JP2024207359A JP2025036429A (ja) 2015-11-13 2024-11-28 プロテアーゼ活性化受容体２のモジュレーター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562255334P 2015-11-13 2015-11-13
US62/255,334 2015-11-13
PCT/US2016/061489 WO2017083618A1 (en) 2015-11-13 2016-11-11 Protease-activated receptor-2 modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022145694A Division JP2022179508A (ja) 2015-11-13 2022-09-13 プロテアーゼ活性化受容体２のモジュレーター

Publications (3)

Publication Number Publication Date
JP2018537529A JP2018537529A (ja) 2018-12-20
JP2018537529A5 JP2018537529A5 (enExample) 2019-12-26
JP7621728B2 true JP7621728B2 (ja) 2025-01-27

Family

ID=57394682

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018544771A Active JP7621728B2 (ja) 2015-11-13 2016-11-11 プロテアーゼ活性化受容体２のモジュレーター
JP2022145694A Pending JP2022179508A (ja) 2015-11-13 2022-09-13 プロテアーゼ活性化受容体２のモジュレーター
JP2024207359A Pending JP2025036429A (ja) 2015-11-13 2024-11-28 プロテアーゼ活性化受容体２のモジュレーター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022145694A Pending JP2022179508A (ja) 2015-11-13 2022-09-13 プロテアーゼ活性化受容体２のモジュレーター
JP2024207359A Pending JP2025036429A (ja) 2015-11-13 2024-11-28 プロテアーゼ活性化受容体２のモジュレーター

Country Status (6)

Country Link
US (2) US11091533B2 (enExample)
EP (1) EP3374386B1 (enExample)
JP (3) JP7621728B2 (enExample)
AU (1) AU2016354478B2 (enExample)
ES (1) ES2984663T3 (enExample)
WO (1) WO2017083618A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination
AU2016354478B2 (en) 2015-11-13 2021-07-22 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
WO2017194716A1 (en) * 2016-05-12 2017-11-16 Astrazeneca Ab Inhibitors of protease-activated receptor-2
AU2019310039A1 (en) * 2018-07-23 2021-02-18 Enclear Therapies, Inc. Methods of treating neurological disorders
KR20220011123A (ko) 2019-04-11 2022-01-27 엔클리어 테라피스, 인크. 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템
EP4055032A1 (en) * 2019-11-07 2022-09-14 The Board Of Trustees Of The University Of Illinois Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation
EP4090372A4 (en) * 2020-01-14 2023-10-18 Mayo Foundation for Medical Education and Research Targeting par1 and par2 to regulate lipid and cholesterol abundance
EP4221801A4 (en) 2020-09-29 2024-11-06 Enclear Therapies, Inc. METHOD AND SYSTEM FOR MANAGING SUBARACHNOID FLUID

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530875A (ja) 2000-04-21 2003-10-21 ニュー イングランド メディカル センター ホスピタル インコーポレイテッド Ｇタンパク質共役型受容体（ｇｐｃｒ）のアゴニストおよびアンタゴニスト、および、それらを用いてｇｐｃｒを活性化および阻害する方法
JP2013504577A (ja) 2009-09-09 2013-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体
JP2014511866A (ja) 2011-04-08 2014-05-19 タフツ メディカル センター インコーポレイテッド ペプデューシンの設計および使用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US5874400A (en) * 1993-07-26 1999-02-23 Cor Therapeutics Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
EP0835928A1 (en) 1996-10-11 1998-04-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Helicobacter pylori live vaccine
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6815200B1 (en) 1998-02-17 2004-11-09 The Uab Research Foundation Modified adenovirus containing a fiber replacement protein
US6503511B1 (en) 1998-04-07 2003-01-07 Medimmune, Inc. Derivatives of choline binding proteins for vaccines
US6562958B1 (en) 1998-06-09 2003-05-13 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
WO2000034469A1 (en) 1998-12-11 2000-06-15 The Research Foundation Of State University Of New York At Albany Compositions and methods for altering cell migration
US6703491B1 (en) 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
US6773893B1 (en) 2000-04-28 2004-08-10 The Trustees Of Columbia University In The City Of New York Human ABC1 promoter and assays based thereon
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
ES2565578T3 (es) 2002-08-02 2016-04-05 South Alabama Medical Science Foundation Vacunas contra el cáncer que contienen epítopos de antígeno oncofetal
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7189691B2 (en) 2004-04-01 2007-03-13 The Administrators Of The Tulane Educational Fund Methods and compositions for treating leukemia
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
US7319142B1 (en) 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
CN101094866A (zh) 2004-11-04 2007-12-26 新英格兰医疗中心医院有限公司 G蛋白耦合受体激动剂和拮抗剂及其使用方法
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
US7739055B2 (en) 2005-11-17 2010-06-15 Massachusetts Institute Of Technology Methods and systems for generating and evaluating peptides
AU2007218045B2 (en) 2006-02-20 2011-11-10 Phylogica Limited Method of constructing and screening libraries of peptide structures
US8586006B2 (en) 2006-08-09 2013-11-19 Institute For Systems Biology Organ-specific proteins and methods of their use
US9056905B2 (en) 2007-05-21 2015-06-16 Alderbio Holdings Llc Antibodies to TNF-α and use thereof
JP4400668B2 (ja) 2007-11-01 2010-01-20 株式会社豊田中央研究所 微小物体が固定化された固相体の製造方法及びその利用
US9029636B2 (en) 2008-02-05 2015-05-12 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
WO2010021822A2 (en) * 2008-07-30 2010-02-25 The Regents Of The University Of California Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
BRPI0921650A2 (pt) 2008-11-04 2019-07-30 Anchor Therapeutics Inc compostos receptores de cxcr4
BRPI0921815A2 (pt) 2008-11-04 2018-10-09 Anchor Therapeutics Inc compostos receptores de apj
US20110039763A1 (en) 2009-01-06 2011-02-17 C3 Jian, Inc. Targeted antimicrobial moieties
US9012723B2 (en) 2009-01-16 2015-04-21 Monsanto Technology Llc Isolated novel acid and protein molecules from soy and methods of using those molecules to generate transgene plants with enhanced agronomic traits
US8389679B2 (en) 2009-02-05 2013-03-05 The Regents Of The University Of California Targeted antimicrobial moieties
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9091651B2 (en) * 2011-12-21 2015-07-28 Integrated Diagnostics, Inc. Selected reaction monitoring assays
AU2016354478B2 (en) 2015-11-13 2021-07-22 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530875A (ja) 2000-04-21 2003-10-21 ニュー イングランド メディカル センター ホスピタル インコーポレイテッド Ｇタンパク質共役型受容体（ｇｐｃｒ）のアゴニストおよびアンタゴニスト、および、それらを用いてｇｐｃｒを活性化および阻害する方法
JP2013504577A (ja) 2009-09-09 2013-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体
JP2014511866A (ja) 2011-04-08 2014-05-19 タフツ メディカル センター インコーポレイテッド ペプデューシンの設計および使用

Also Published As

Publication number Publication date
US20210061883A1 (en) 2021-03-04
JP2022179508A (ja) 2022-12-02
AU2016354478B2 (en) 2021-07-22
JP2018537529A (ja) 2018-12-20
US11732027B2 (en) 2023-08-22
AU2016354478A1 (en) 2018-05-31
EP3374386C0 (en) 2024-05-29
EP3374386A1 (en) 2018-09-19
US11091533B2 (en) 2021-08-17
EP3374386B1 (en) 2024-05-29
ES2984663T3 (es) 2024-10-30
WO2017083618A1 (en) 2017-05-18
CA3005029A1 (en) 2017-05-18
US20170137492A1 (en) 2017-05-18
JP2025036429A (ja) 2025-03-14

Similar Documents

Publication Publication Date Title
JP7621728B2 (ja) プロテアーゼ活性化受容体２のモジュレーター
KR102068370B1 (ko) 심부전의 치료를 위한 합성 아펠린 모방체
EP2697386B1 (en) Pepducin design and use
JP6069663B2 (ja) 抗炎症医薬製品
US11376305B2 (en) Compositions and methods for regulating blood pressure
JP2021515759A (ja) コンプスタチン類似体及びその医療用途
US11572399B2 (en) Long-acting GIP peptide analogues
KR20230039718A (ko) 보체 인자 c3의 억제제 및 이들의 의학적 용도
JP2022545916A (ja) コンプスタチン類似体及びその医学的使用
CN109718363B (zh) 预防、缓解或治疗阿尔茨海默病的肽及其应用
CA3005029C (en) Protease-activated receptor-2 modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220913

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220913

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221109

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221110

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221228

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250115

R150 Certificate of patent or registration of utility model

Ref document number: 7621728

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150